HC Wainwright Comments on Kura Oncology Q2 Earnings

Kura Oncology, Inc. (NASDAQ:KURA - Free Report) - Research analysts at HC Wainwright issued their Q2 2025 earnings estimates for Kura Oncology in a research note issued on Thursday, February 27th. HC Wainwright analyst J. Pantginis forecasts that the company will earn ($0.81) per share for the quarter. HC Wainwright currently has a "Buy" rating and a $40.00 target price on the stock. The consensus estimate for Kura Oncology's current full-year earnings is ($2.44) per share. HC Wainwright also issued estimates for Kura Oncology's FY2025 earnings at ($3.14) EPS, FY2026 earnings at ($3.75) EPS, FY2027 earnings at ($4.24) EPS, FY2028 earnings at ($2.34) EPS and FY2029 earnings at ($1.12) EPS.

Kura Oncology (NASDAQ:KURA - Get Free Report) last announced its quarterly earnings data on Wednesday, February 26th. The company reported ($0.22) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.65) by $0.43. The firm had revenue of $53.88 million for the quarter, compared to analysts' expectations of $57.96 million.

KURA has been the subject of several other research reports. BTIG Research lowered shares of Kura Oncology from a "buy" rating to a "neutral" rating in a research report on Thursday, February 6th. Wedbush restated an "outperform" rating and set a $36.00 price objective on shares of Kura Oncology in a report on Thursday, February 27th. StockNews.com raised Kura Oncology from a "sell" rating to a "hold" rating in a research report on Thursday, February 27th. UBS Group lowered their price target on Kura Oncology from $27.00 to $14.00 and set a "buy" rating for the company in a research report on Thursday. Finally, Bank of America cut their price objective on Kura Oncology from $36.00 to $29.00 and set a "buy" rating on the stock in a report on Friday, November 22nd. Four research analysts have rated the stock with a hold rating, seven have issued a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus target price of $25.50.

Remove Ads

Kura Oncology Trading Up 4.5 %

KURA traded up $0.33 during midday trading on Monday, hitting $7.70. The company's stock had a trading volume of 1,438,284 shares, compared to its average volume of 1,598,446. Kura Oncology has a 52-week low of $6.98 and a 52-week high of $24.17. The firm has a 50-day moving average price of $8.04 and a two-hundred day moving average price of $13.51. The company has a current ratio of 11.47, a quick ratio of 11.47 and a debt-to-equity ratio of 0.02. The firm has a market cap of $598.78 million, a P/E ratio of -3.26 and a beta of 0.85.

Insider Activity at Kura Oncology

In other news, SVP Thomas James Doyle sold 4,949 shares of the business's stock in a transaction that occurred on Tuesday, January 28th. The stock was sold at an average price of $7.87, for a total value of $38,948.63. Following the completion of the sale, the senior vice president now directly owns 88,193 shares in the company, valued at approximately $694,078.91. The trade was a 5.31 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Mollie Leoni sold 4,963 shares of the company's stock in a transaction that occurred on Tuesday, January 28th. The shares were sold at an average price of $7.87, for a total value of $39,058.81. Following the sale, the insider now directly owns 88,253 shares in the company, valued at approximately $694,551.11. This represents a 5.32 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 11,729 shares of company stock valued at $92,307. Insiders own 5.50% of the company's stock.

Institutional Trading of Kura Oncology

Several hedge funds have recently made changes to their positions in the stock. RA Capital Management L.P. acquired a new stake in shares of Kura Oncology in the fourth quarter valued at approximately $38,769,000. Millennium Management LLC grew its holdings in Kura Oncology by 180.1% in the 4th quarter. Millennium Management LLC now owns 2,367,148 shares of the company's stock worth $20,618,000 after buying an additional 1,521,954 shares in the last quarter. Jacobs Levy Equity Management Inc. acquired a new stake in Kura Oncology in the 4th quarter valued at approximately $8,518,000. Marshall Wace LLP bought a new stake in Kura Oncology during the 4th quarter valued at $8,265,000. Finally, D. E. Shaw & Co. Inc. boosted its position in Kura Oncology by 172.0% during the 4th quarter. D. E. Shaw & Co. Inc. now owns 1,151,195 shares of the company's stock worth $10,027,000 after acquiring an additional 727,987 shares during the period.

Kura Oncology Company Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.